^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
Published date:
10/27/2020
Excerpt:
...we aimed to investigate the clinical value of obesity in BC patients treated with anti-HER2 therapies in the NeoALTTO trial, which randomized 455 patients to neo-adjuvant lapatinib, trastuzumab, or their combination plus paclitaxel....Among 454 patients analyzed, 14 (3%), 220 (48%), 137 (30%), and 83 (18%) were classified as underweight, normal weight, overweight, and obese, respectively; 231 (51%) and 223 (49%) had hormone receptor (HR)-positive and HR-negative primary tumors; 160 (35%) achieved pCR....NeoALTTO patients overweight or obese at baseline and with HR-positive primary BC appeared less likely to achieve pCR after neo-adjuvant anti-HER2 therapies. This finding paves the way to future research in targeting the interplay between HER2/HR signaling and metabolism.
Secondary therapy:
paclitaxel
DOI:
10.1186/s13058-020-01356-w
Trial ID:
Source:
Title:
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)
Excerpt:
...while if a patient is HR positive(ER and/or PR ≥10%）,the longest diameter of invasive cancer is greater than 1cm and...
Trial ID:
Source:
Title:
A Clinical Study on Hormone Receptor Positive HER2 Positive Breast Cancer of RCB1-2 After Neoadjuvant Treatment With Trastuzumab Combined With Parezumab
Excerpt:
...Hormone receptor positive (definition: immunohistochemistry estrogen receptor ≥ 1%, and/or progesterone receptor ≥ 1%), HER2 positive (definition: standard immunohistochemistry 3+or ISH positive); 6....
Trial ID:
More C2 evidence
Source:
Title:
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
Excerpt:
...Adjuvant tamoxifen or aromatase inhibitors treatment will be allowed for hormone receptor-positive patients....
Trial ID:
Source:
Title:
Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Excerpt:
...Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR`Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream...
Trial ID:
Source:
Title:
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)
Excerpt:
...while if a patient is HR positive(ER and/or PR ≥10%）,the longest diameter of invasive cancer is greater than 1cm and...
Trial ID:
Source:
Title:
PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer
Excerpt:
...- Hormone receptor-positive disease and planning to receive treatment with neoadjuvant aromatase inhibitor and ovarian suppression therapy (if premenopausal)...
Trial ID:
Source:
Title:
PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
Excerpt:
...Pathological complete response in the breast and axilla (pCRBL) to dual HER2 blockade with lapatinib and trastuzumab, in all patients, at the time of surgery, predicted by PAM50 HER2-E subtype`Residual cancer burden in the breast (RCB) to dual HER2 blockade with lapatinib and trastuzumab, in all patients, at the time of surgery, predicted by PAM50 HER2-E subtype`Changes in the percentage of Ki67-positive cells in PAM50 non-Luminal A/B (combined) subtypes`Gene expression variations in all patients, in HR-negative and in HR-positive patients`Correlation between PAM50 HER2-E centroid, as a continuous variable, and pCR and/or RCB in the breast to dual HER2 blockade with lapatinib and trastuzumab at the time of surgery`Identification of additional gene expression signatures beyond the PAM50 subtypes that predict pCR and/or RCB to dual HER2 blockade with lapatinib and trastuzumab at the time of surgery`PAM50 risk of relapse (ROR) score and its ability to predict pCR and/or RCB in the breast to dual HER2 blockade with lapatinib and trastuzumab at the time of surgery in all patients and in those with HR-positive and HR-negative disease`PAM50 HER-2 subtype (PAM50 HER2-E signature) ability as a continuous variable to predict pCRB to dual HER2 blockade at the time of surgery in patients with HR-positive disease and in patients with HR-negative disease`Changes in gene expression from day 0 to day 14, after dual HER2 blockade, that predict pCRB in all patients and in those with HR-positive and HR-negative disease`Frequency of adverse events (AE) when lapatinib plus trastuzumab, with or without endocrine therapy, is administered in the neoadjuvant setting...
Trial ID:
Source:
Title:
This is an early stage breast cancer trial for women who have low expression of a biological protein called Her 2.Patients will have either node positive disease or high risk node negative disease. Patients will be assigned to receive chemotherapy alone or chemotherapy +Trastuzumab in a completely random fashion.
Excerpt:
...If ER analysis is negative, then PgR analysis must also be performed.Either the core biopsy or surgical resection specimen can be used for ER/PgR testing.) Patients with a primary tumor that is hormone receptor-positive or receptor-negative are eligible. ...
Trial ID:
